harvard biosci - HBIO

HBIO

Close Chg Chg %
4.91 0.83 16.90%

Closed Market

5.74

+0.83 (16.90%)

Volume: 119.01K

Last Updated:

Apr 15, 2026, 4:00 PM EDT

Company Overview: harvard biosci - HBIO

HBIO Key Data

Open

$4.90

Day Range

4.90 - 5.82

52 Week Range

2.81 - 9.46

Market Cap

$21.96M

Shares Outstanding

4.47M

Public Float

N/A

Beta

1.50

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$12.85

Yield

0.00%

Dividend

$1.35

EX-DIVIDEND DATE

Nov 4, 2013

SHORT INTEREST

N/A

AVERAGE VOLUME

78.03K

 

HBIO Performance

1 Week
 
13.92%
 
1 Month
 
3.70%
 
3 Months
 
-16.38%
 
1 Year
 
26.55%
 
5 Years
 
-92.96%
 

HBIO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About harvard biosci - HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, China, United Kingdom, and Rest of the World. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

HBIO At a Glance

Harvard Bioscience, Inc.
84 October Hill Road
Holliston, Massachusetts 01746-1371
Phone 1-508-893-8999 Revenue 86.55M
Industry Medical Specialties Net Income -56,700,000.00
Sector Health Technology Employees 339
Fiscal Year-end 12 / 2026
View SEC Filings

HBIO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.343
Price to Book Ratio 2.178
Price to Cash Flow Ratio 4.41
Enterprise Value to EBITDA 10.811
Enterprise Value to Sales 0.755
Total Debt to Enterprise Value 0.678

HBIO Efficiency

Revenue/Employee 255,309.735
Income Per Employee -167,256.637
Receivables Turnover 5.395
Total Asset Turnover 0.837

HBIO Liquidity

Current Ratio 2.196
Quick Ratio 1.249
Cash Ratio 0.392

HBIO Profitability

Gross Margin 53.013
Operating Margin 0.116
Pretax Margin -66.304
Net Margin -65.511
Return on Assets -54.858
Return on Equity -147.131
Return on Total Capital -97.74
Return on Invested Capital -89.852

HBIO Capital Structure

Total Debt to Total Equity 322.39
Total Debt to Total Capital 76.325
Total Debt to Total Assets 55.297
Long-Term Debt to Equity 311.286
Long-Term Debt to Total Capital 73.696
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Harvard Biosci - HBIO

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
113.33M 112.25M 94.14M 86.55M
Sales Growth
-4.68% -0.96% -16.14% -8.06%
Cost of Goods Sold (COGS) incl D&A
57.17M 51.38M 44.58M 40.67M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
7.58M 7.00M 6.98M 5.95M
Depreciation
1.45M 1.47M 1.73M 1.74M
Amortization of Intangibles
6.12M 5.53M 5.25M 4.20M
COGS Growth
+0.13% -10.12% -13.24% -8.78%
Gross Income
56.17M 60.87M 49.55M 45.88M
Gross Income Growth
-9.13% +8.36% -18.59% -7.41%
Gross Profit Margin
+49.56% +54.22% +52.64% +53.01%
2022 2023 2024 2025 5-year trend
SG&A Expense
60.88M 58.58M 54.11M 45.78M
Research & Development
12.33M 11.76M 10.41M 8.82M
Other SG&A
48.55M 46.82M 43.70M 36.96M
SGA Growth
+4.12% -3.77% -7.63% -15.39%
Other Operating Expense
- - - 62.00K
-
Unusual Expense
1.46M 823.00K 3.25M 48.68M
EBIT after Unusual Expense
(6.23M) 1.46M (7.80M) (48.58M)
Non Operating Income/Expense
(398.00K) (427.00K) (652.00K) (3.89M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.55M 3.59M 3.21M 4.92M
Interest Expense Growth
+65.45% +40.93% -10.64% +53.23%
Gross Interest Expense
2.55M 3.59M 3.21M 4.92M
Interest Capitalized
- - - -
-
Pretax Income
(9.18M) (2.56M) (11.66M) (57.39M)
Pretax Income Growth
-6,456.43% +72.15% -356.38% -391.95%
Pretax Margin
-8.10% -2.28% -12.39% -66.30%
Income Tax
337.00K 859.00K 740.00K (686.00K)
Income Tax - Current - Domestic
641.00K 570.00K 140.00K (6.00K)
Income Tax - Current - Foreign
194.00K 61.00K 290.00K (127.00K)
Income Tax - Deferred - Domestic
(468.00K) 132.00K (70.00K) (431.00K)
Income Tax - Deferred - Foreign
(30.00K) 96.00K 380.00K (122.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(9.52M) (3.42M) (12.40M) (56.70M)
Minority Interest Expense
- - - -
-
Net Income
(9.52M) (3.42M) (12.40M) (56.70M)
Net Income Growth
-3,204.17% +64.11% -263.25% -357.07%
Net Margin Growth
-8.40% -3.04% -13.18% -65.51%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(9.52M) (3.42M) (12.40M) (56.70M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(9.52M) (3.42M) (12.40M) (56.70M)
EPS (Basic)
-2.2978 -0.805 -2.8492 -12.7729
EPS (Basic) Growth
-3,118.21% +64.97% -253.94% -348.30%
Basic Shares Outstanding
4.14M 4.24M 4.35M 4.44M
EPS (Diluted)
-2.2978 -0.805 -2.8492 -12.7729
EPS (Diluted) Growth
-3,118.21% +64.97% -253.94% -348.30%
Diluted Shares Outstanding
4.14M 4.24M 4.35M 4.44M
EBITDA
2.80M 9.28M 2.42M 6.04M
EBITDA Growth
-74.43% +231.18% -73.88% +149.28%
EBITDA Margin
+2.47% +8.27% +2.58% +6.98%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 20.00
Number of Ratings 2 Current Quarters Estimate -3.90
FY Report Date 06 / 2026 Current Year's Estimate -14.60
Last Quarter’s Earnings -6.05 Median PE on CY Estimate N/A
Year Ago Earnings -0.20 Next Fiscal Year Estimate 0.80
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 1
Mean Estimate -3.90 -3.60 -14.60 0.80
High Estimates 0.00 0.10 0.20 0.80
Low Estimate -7.80 -7.30 -29.40 0.80
Coefficient of Variance -141.42 -145.35 -143.36 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Harvard Biosci - HBIO

Date Name Shares Transaction Value
Apr 2, 2026 Mark T. Frost Chief Financial Officer 17,500 Open market or private purchase of non-derivative security Non-derivative transaction at $5 per share 87,500.00
Aug 20, 2025 James W. Green Director 2,796,040 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Aug 20, 2025 James W. Green Director 2,762,840 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.53 per share 1,464,305.20
Aug 20, 2025 James W. Green Director 2,643,508 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Aug 20, 2025 James W. Green Director 2,631,968 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.53 per share 1,394,943.04
Aug 20, 2025 James W. Green Director 2,565,905 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Aug 20, 2025 James W. Green Director 2,452,566 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00

Harvard Biosci in the News